Compare Global X Copper Miners ETF (COPX) vs Quest Diagnostics Inc (DGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Global X Copper Miners ETF vs Quest Diagnostics Inc — how do they compare? Global X Copper Miners ETF trades at $85.75 (market cap $7.10B), while Quest Diagnostics Inc trades at $230.97 (market cap $25.48B). The key difference: Quest Diagnostics Inc is far larger — about 3.6× Global X Copper Miners ETF's market cap, and Quest Diagnostics Inc pays a 1.49% dividend while Global X Copper Miners ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Global X Copper Miners ETF for 51 Days and Quest Diagnostics Inc for 56 Days on average.
| COPX | DGX | |
|---|---|---|
Market Cap | $7.10B | $25.48B |
Volume | 2,871,128 | 941,866 |
Sector | Commodities - Metals/Agriculture | Health |
52-Week High | $96.45 | $247.45 |
52-Week Low | $57.43 | $173.49 |
Typical Hold Time | 51 Days | 56 Days |
Enterprise Value | — | $31.23B |
Dividend Yield | — | 1.49% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
COPX (Global X Copper Miners ETF) trades at $82.22, down 1.63% today amid bearish technical signals. The ETF faces selling pressure with 13 bearish moving average signals versus zero bullish. Copper fundamentals remain strong with prices near all-time highs above $6.85 per pound, driven by AI infrastructure demand and supply constraints. Recent news highlights copper's critical role in electrification and AI infrastructure, though technical indicators suggest near-term weakness.
The long-term copper thesis remains compelling due to structural supply deficits and AI-driven demand, but near-term technical weakness and Federal Reserve policy uncertainty create volatility. Mining equities currently trade at a discount to copper futures, offering potential value. Key risks include global copper surplus projections and macroeconomic sensitivity.
Quest Diagnostics (DGX) trades at $230.81, up 1.68% today, with a bullish earnings trend after beating EPS estimates for three consecutive quarters. The stock shows a mixed technical picture with a bearish overall signal but trades near key support at $228. Revenue growth accelerated to $11.04B in 2025, and the company maintains solid profitability with a 9.19% net income margin. Recent news highlights growth in consumer testing and a partnership with Apple Health, though Medicare reimbursement cuts pose a headwind.
The outlook is cautiously optimistic, supported by strong fundamentals and a consensus price target of $250 offering 8% upside. Key opportunities include demand for advanced diagnostics and AI adoption, while risks center on regulatory pressure and rising debt levels. Analyst sentiment is mixed with a slight hold bias, reflecting balanced growth prospects against near-term challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Global X Copper Miners ETF
COPX tracks the Solactive Global Copper Miners Total Return Index, providing broad exposure to companies worldwide involved in copper mining, refining, and exploration. It serves as an equity-based alternative to copper futures, offering a leveraged play on copper demand driven by global infrastructure and the clean energy transition.
Read more on COPX →About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →
